Serum IGF-I Is Not a Reliable Pharmacodynamic Marker of Exogenous Growth Hormone Activity in Mice
Maximilian Bielohuby(Sanofi (Germany)), Martin Bidlingmaier(LMU Klinikum)
Cited by 22
Related Papers
Treatment of Acromegaly with the Growth Hormone–Receptor Antagonist Pegvisomant
|New England Journal of Medicine|2000|874
Diagnosis, Genetics, and Therapy of Short Stature in Children: A Growth Hormone Research Society International Perspective
|Hormone Research in Paediatrics|2019|345
Steroid metabolome analysis reveals prevalent glucocorticoid excess in primary aldosteronism
|JCI Insight|2017|275
Growth Hormone Research Society perspective on the development of long-acting growth hormone preparations
|European Journal of Endocrinology|2016|144
Safety of growth hormone replacement in survivors of cancer and intracranial and pituitary tumours: a consensus statement
|European Journal of Endocrinology|2022|111